cyrilzakka/clinical-trials huggingface dataset:
Impact of a Magnetic Resonance Imaging (MRI) Scanner Exclusively Dedicated to Emergency in the Clinical Management of Patients Presenting With Diplopia or Dizziness

IRM-DU is a prospective observational single center study conducted in an emergency department to evaluate the impact of a MRI scanner exclusively dedicated to emergency in the clinical management of patients presenting with dizziness or diplopia.

The study will compare 2 strategies : after and before availability of a MRI scanner dedicated to emergency.

The primary endpoint is the proportion of patients with a diagnosis of stroke confirmed by imaging (MRI or Computed tomography (CT)) in the group "before implementation of the emergency MRI scanner" and the group "after implementation of the emergency MRI scanner".

The hypothesis is that the availability of a MRI scanner dedicated to emergency will improve the diagnosis of stroke in patients presenting with dizziness or diplopia, and will reduce Emergency Department stay, hospital stay and hospitalisation costs.


Eligibility Criteria:
Inclusion Criteria:

* age over 18 years
* non opponent to participate
* dizziness or diplopia requiring brain imaging in order to eliminate stroke

Exclusion Criteria:

* opponent to participate
* pregnant women
* recent cerebral trauma
* potentially eligible to thrombolysis
* impaired consciousness
* unable to give consent
TULIP et MASC : Premiers Usages

The aim of this work is to propose two new questionnaires (TULIP and MASC) which are simple to complete by the patient, quick to analyze and can be calculated directly by the physician, adapted to the general population, whether during an initial evaluation or for follow-up.

The TULIP questionnaire aims to characterize the symptoms suggestive of Thoracic Outlet Syndrome (TOS). The MASC questionnaire aims to assess the functional maintenance of TOS in a simpler way (fewer questions) than the Disability of the Arm, Shoulder and Hand (DASH) questionnaire and in a lateralized way.

Two questionnaires the TULIP and the MASC are submitted (self completion) to patients suspected of TOS.

Eligibility Criteria:
Inclusion Criteria:

* Suspicion of Thoracic Outlet Syndrome

Exclusion Criteria:

Non applicable
Verbal and Visual Information Techniques on Anxiety in Third Molar Surgery

The aim of this study was to evaluate preoperative anxiety levels using dental anxiety scale (DAS) and the Spielberger State-Trait Anxiety Inventory (STAI).

This study will based on a prospective, observational investigation of two different patient education techniques about the effect of third molar removal on patients' anxiety level. A total of 240 patients will be divided into two groups.

Information about operation procedures and a recovery will be given verbally in group 1 and information about operation procedures and recovery will be given in group 2. Anxiety levels were assessed by using DAS and (STAI).Paired t-test or Wilcoxon test will be used for intra-group comparison of anxiety levels.

Eligibility Criteria:
Inclusion Criteria:

* Impacted third molar (bone and mucosa retention, mesioangular position)
* Patients with any chronic disease and allergy

Exclusion Criteria:

* Pericoronitis
* Patients with visual impairment
* Patients with psychological disorders
* Smoking
* Pregnancy or lactation
Initiation of Colon Cancer Screening in Veterans or "Start Screening Now"

Initiation of colon cancer screening in veterans is a theory-based stepped intervention to increase first time colorectal cancer screening (CRCS) among male and female veterans age 50 and over.

Colorectal cancer (CRC) is the 2nd leading cause of cancer deaths in the US and risk increases with age. Colorectal cancer screening (CRCS) offers the possibility of both early detection and prevention. For those at average risk, CRCS beginning at age 50 is recommended. However, awareness and use of CRCS tests are low. We propose to conduct a randomized controlled trial to develop and test stepped interventions to increase initial uptake of CRCS in a nationally-representative, ethnically-diverse sample of male and female veterans. Our specific aims are to: (1) develop and pre-test stepped intervention components that are theory and evidence-informed; (2) implement and evaluate the process, efficacy, and cost-effectiveness of stepped interventions to increase an initial CRCS among male and female veterans aged 50-64 years; and (3) analyze the association between predictor variables and CRCS initiation and the mediating and moderating effects of the interventions, after each step. In Step 1, we will evaluate a theory-based minimal cue delivered by a letter, telephone call, or automated telephone call compared with a survey-only control group to determine whether the 3 different delivery channels are equally efficacious and cost-effective. Minimal cues are a cost-effective method that prompts to action those more willing to change and are easy to disseminate in real-world settings. Persons who do not complete CRCS in Step 1 will be randomized in Step 2 to more intensive interventions that address resistance. In Step 2 we will determine whether a theory-based, tailored telephone intervention, using principles of Motivation Interviewing, is effective when delivered as part of a sequential intervention process in which early adopters have been removed from the population. Step 2 also will determine whether an automated approach, telephone-linked communication (TLC), is as effective as a telephone counselor in promoting initiation of CRCS. Steps 1 and 2 together will address the important issue of the "dose" needed to encourage completion of CRCS. After each step, we will examine the mediating and moderating effects of the intervention to identify determinants of completion. For cancer screening intervention research to have the broadest public health impact, interventions must have the potential for dissemination. We designed our trial to move us toward the goal of disseminable interventions with evidence of external validity.

Eligibility Criteria:
Inclusion Criteria:

* Male or Female Veteran age 50 to 64

Exclusion Criteria:

* Prior CRCS
* History of colon or bowel cancer, Crohn's disease, ulcerative colitis
* History of colon polyps
* Currently active duty military
* Outside of age range
Improving Health of Patients With Colon Cancer Following Surgery: A Trial of SA-ICAN Via Videoconferencing

The purpose of this study is to assess the impact of more frequent follow-up (by videoconference) of these patients. Videoconference is a method of communication over a distance. In this method, the patient will hear the person's voice (like on the telephone) and will see that person over video.

The study will compare more frequent follow-up of patients by videoconferencing to routine follow-up of patients. The investigators will compare each type of follow-up to see the effect on the number of times patients need to visit emergency rooms or need admission to hospitals. The study will also look at the difference between each type of follow-up on patients' quality of life and social support thirty days after hospital discharge.

The study will also measure satisfaction and acceptability of this intervention among those who had follow-ups by videoconference.


Eligibility Criteria:
Inclusion Criteria:

* Age 65 or older.
* Newly diagnosed cancer.
* Referred to the geriatrics service for pre-operative evaluation before surgical resection of his/her tumor.

Exclusion Criteria:

* Inability to comprehend English.
* Deafness , measured by the Hearing Handicap Inventory for the Elderly Screening Version (HHIE-S) \[16\], score equal or above 30. (appendix 5)
* Cognitive impairment (score of 0-1 in Mini-Cog Test).
* Nursing home resident.
* Planned hospital length of stay of one day or less.
Assessment of the Risk of Contralateral Non Simultaneous Neck of Femur Fracture in the Elderly.

Neck of femur fractures are common in the elderly and are the source of significant morbidity and mortality. This study is based on a new technique developed in Ben Gurion University, with which investigators are able to asses the structural 3 dimensional strength of a bone by applying a unique simulation on a CAT scan of the bone. The purpose of this study is to evaluate the risk of a contralateral neck of femur fracture after the first neck of femur fracture and to estimate the potential fracture characteristics.

Neck of femur fractures are common in the elderly and are the source of significant morbidity and mortality. literature shows that around 10 percent of those who fracture their femoral neck for the first time will later fracture their contralateral neck of femur and in most cases with the same fracture characteristics. This study is based on a new technique developed in Ben Gurion University, with which investigators are able to asses the structural 3 dimensional strength of a bone by applying a unique simulation on a CAT scan of the bone. The purpose of this study is to evaluate the risk of a contralateral neck of femur fracture after the first neck of femur fracture and to estimate the potential fracture characteristics.

Eligibility Criteria:
Inclusion Criteria:

* 70-90 years old patients admitted to the orthopaedic department after neck of femur fracture.
* No contra lateral femur pathology.
* Consent for pelvis and femurs CAT scan.

Exclusion Criteria:

* Known pathology in other lower limbs joints in the body.
* History of previous fractures or operations in lower limbs.
Single-level and Two-level Serratus Posterior Superior Intercostal Plan Block (SPSIPB)

Breast cancer is the most common malignancy in women; one of the mainstays of breast cancer treatment is surgery, and modified radical mastectomy is one of the standard treatments. Postoperative pain can seriously reduce the quality of life in patients, and acute pain can even trigger chronic pain syndrome. Thoracic paravertebral, thoracic epidural, intercostal nerve, and interscalene brachial plexus blocks have been used for anesthesia and abrigation during modified radical mastectomy, but their applications are limited due to the complex nature of the procedures and serious complications. In recent years, regional nerve blocks, including intercostal nerve block, erector spinae plane block (ESPB), and paravertebral block, PECS I-II block, serratus anterior plane block (SAPB), and Serratus Posterior Superior Intercostal Plane Block (SPSIPB), have been applied for the treatment of postmastectomy pain in breast cancer patients. SPSIPB has been frequently used for the treatment of acute pain in the postoperative period following surgeries in the thoracic region. SPSIPB is placed on the spine of the scapula in the sagittal plane to identify the second and third ribs under USG guidance. After visualizing the trapezius and serratus posterior superior (SPS) by moving medially to the upper medial border of the scapula, a block is applied to the depths of the SPS from above the 3rd rib. The applied local anesthetic solution spreads under the SPS muscle. Ipsilateral postoperative analgesia is provided with SPSIPB. SPSIPB can be applied on the 3rd rib in one go, or on the 3rd and 4th ribs in two go. Thus, the local anesthetic solution can be distributed more effectively and more effective postoperative analgesia can be provided.


Eligibility Criteria:
Inclusion Criteria:

1-Those between the ages of 18-80

2.Those with ASA score I-II-III

3.Those with body mass index (BMI) between 18-40

4.Patients who underwent Single-Level or Two-Level SPSIPB together with mastectomy in the operating room

Exclusion Criteria:

1. Those under 18 and over 80
2. Those with ASA score IV and above
3. Those with advanced co-morbidities
4. Those with a history of bleeding diathesis
5. Patients with infection in the area where the block will be performed
6. Those with BMI under 18 and over 40
7. Patients who underwent surgery under emergency conditions
Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer.

The goal of this clinical trial is to learn about Fruquintinib combined with Adebrelimab and high and low dose radiotherapy in the treatment of second-line and above failure MSS(microsatellite stability) metastatic colorectal cancer.

The main question it aims to answer is: The efficacy and safety of Fruquintinib combined with Adebrelimab and high and low dose radiotherapy in the third line and beyond treatment of MSS metastatic colorectal cancer.

Participants will receive the combination of Fruquintinib and Adebrelimab within 3 weeks after completion of high and low dose radiotherapy on metastases until disease progression or intolerable toxicity occurred.


Eligibility Criteria:
Inclusion Criteria:

1. Age ≥ 18 years old, gender not limited；
2. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score 0-1；
3. Previously identified as MSS type mCRC；
4. Metastatic colorectal cancer (mCRC) with disease progression after receiving standard second-line treatment according to Chinese Society of Clinical Oncology ( CSCO) guidelines；
5. At least one measurable lesion (RECIST 1.1)；
6. Be able to adhere to the protocol during the research period；
7. Sign the informed consent form.

Exclusion Criteria:

1. For individuals with a history of uncontrolled epilepsy, central nervous system disorders, or mental disorders, the clinical severity of which may hinder the signing of informed consent forms or affect the patient's adherence to oral medication, as determined by the researcher；
2. Accompanied by other malignant tumors that have not been cured；
3. The baseline blood routine and biochemical indicators of the subject do not meet the following criteria: hemoglobin ≥ 90g/L; Absolute neutrophil count (ANC) ≥ 1.5 × 109/L; Platelets ≥ 100 × 109/L; Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ≤ 2.5 times the normal upper limit; Alkaline phosphatase (ALP) ≤ 2.5 times the normal upper limit value; Serum total bilirubin\<1.5 times the normal upper limit value; Serum creatinine\<1 times the upper limit of normal; Serum albumin ≥ 30g/L；
4. Serious (i.e. active) heart disease in clinical practice, such as symptomatic coronary heart disease, congestive heart failure, or severe arrhythmia requiring medication intervention, or a history of myocardial infarction in the past 12 months；
5. Irreversible coagulation dysfunction or concurrent active massive bleeding；
6. Combination of active infections requiring antibiotic treatment；
7. Individuals who are allergic to any research drug ingredients；
8. Women with concurrent pregnancy or lactation；
9. Organ transplantation requires immunosuppressive therapy and long-term hormone therapy；
10. Patients with autoimmune diseases；
11. There is a history of drug treatment in previous plans。
Feasibility and Acceptability of Endoscopic Mastectomy in Patients With Breast Cancer

Nipple -Sparing Mastectomy (NSM), with immediate breast reconstruction (IBR) can be offered to patients requiring mastectomy when the lesion is more than 2cm from the nipple. Endoscopic mastectomy is a technical alternative for small-volume breasts (cup sizes A, B, C), offering a NSM with IBR, but also concealing the scar on the axillary line. It can be performed with traditional laparoscopic equipment, making this technique much more accessible and less costly than robotic mastectomy. It uses a single-port device that is significantly less costly than robotic equipment.

Feasibility and safety studies remain limited to the Asian continent, and it would undoubtedly be beneficial to initiate research in Europe to add this new technical option to our surgical arsenal. This study project aims to explore the feasibility and safety of endoscopic nipple-sparing mastectomy for breast cancer indications in a French center.

It s a practicability study, evaluating endoscopic approach for mastectomy, using an axillary single port in breast cancer patients. Conventional surgery conversion rate, operative time, infectious rate, esthetical outcomes, oncological safety and functional outcomes will be evaluated.

Eligibility Criteria:
Inclusion Criteria:

* Women between 20 and 75 years.
* Patient with an indication for curative mastectomy, either unilateral or bilateral, with nipple preservation:

  * Extensive Carcinoma In Situ (CIS), more than 2 cm from the nipple
  * Multicentric Infiltrating Carcinoma (IC), more than 2 cm from the nipple
  * Large volume Infiltrating Carcinoma, more than 2 cm from the nipple
  * IC or CIS for which the patient refuses conservative treatment, more than 2 cm from the nipple
* Breast volumes: cup sizes A, B, or C as defined by underwear size, and glandular ptosis not exceeding grade 2 according to Regnault's classification
* Patient wishing to undergo immediate breast reconstruction.
* WHO/OMS (World Health Organization/Organisation Mondiale de la Santé) performance status \<3

Exclusion Criteria:

* Cutaneous carcinoma
* Inflammatory breast
* History of oncological breast surgery on the same breast
* Patient who has received radiation treatment on the same breast
* Breast hypertrophy requiring a nipple-bearing flap
* Smoking ≥ 10 cigarettes/day
* BMI \> 35
* Protected patient or unable to give consent according to Article L1121-8 of the French Public Health Code (CSP).
* Patient participating in another interventional clinical study.
* ASA (physical status score of the American Society of Anesthesiologists) \>2.
* Pregnant or breastfeeding women according to Article L1121-5 of the CSP.
* Vulnerable persons (those receiving psychiatric care, those deprived of liberty, and those admitted to a health or social institution) according to Article L1121-6 of the CSP.
* Absence of effective contraception for patients of childbearing age.
* Absence of affiliation with a social security scheme.
* Absence of collected free, informed, and written consent.
Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide

Prospective, non-comparative, non-interventional, observational study to collect and analyse real life environment data on advanced prostate cancer patients receiving combination treatment of medical or surgical castration and bicalutamide according to routine medical practice in Croatia. The main aim is to evaluate change of PSA level and prescribing practices based on prostate cancer stage.


Eligibility Criteria:
Inclusion Criteria:

* Patients with diagnosis of advanced prostate cancer
* Patients who are already treated with bicalutamide for at least 4 weeks and maximum 12 weeks
* Patients capable of signing ICF

Exclusion Criteria:

* Patients with hypersensitivity to bicalutamide
* Patients on therapy with terfenadin, astemizol or cisapride
* Participation in a clinical study during the last 30 days
Vaccination Against Influenza Pre-discharge in Heart Failure

In patients with heart failure (HF), influenza vaccination should be considered to prevent HF hospitalizations. However, vaccination rates among patients with HF are low, in part because of subjective but common concerns about whether patients with such severe disease should be vaccinated. In this randomized, open-label study, we will investigate whether influenza vaccination before discharge in patients stabilized after cardiac decompensation is safe and improves outcomes over a 6-month follow-up period.


Eligibility Criteria:
Inclusion Criteria:

* informed consent to participate in the study
* hospitalization (unplanned) due to exacerbation (decompensation) of heart failure
* planned discharge within the next 48 hours due to completion of hospital treatment
* no current (2024/25 season) influenza vaccination.

Exclusion Criteria:

* severe post-vaccination reaction during influenza vaccination in any previous influenza season
* hypersensitivity to any of the components of the vaccine planned to be administered
* discharge to another hospital for continued treatment or discharge to a nursing home
* antibiotic therapy among the drugs recommended for taking after hospitalization.
Safety and Efficacy of Apixaban in Very Old Geriatric Subjects (> 80 Years) With Atrial FIbrillation in a Prospective reAl World Study;

The main objective of this study is to realize an observational "real life" study conducted in French geriatric settings, to assess safety and efficacy in ≥ 80 year-old patients with nonvalvular Atrial fibrillation (AF) newly treated with Apixaban.

Moreover, in this geriatric population the adequacy of Apixaban dosage and events (bleeding and stroke) will be assessed.

It is a muliticentric, observational, prospective study.

This study will be conducted in about 40 geriatric settings in France.

The planned duration of the inclusion period is 27 months in each center.

The follow-up period starts from inclusion up to one year after inclusion with phone contact or unscheduled visit at 3, 6, 9 and 12 months.

During this follow-up, participants physicians will record patients' data during visit directly from the patients or their physicians or their families and by phone.

The following data will be colllected:

* At M0 : Socio-demographics, clinical and biological data; embolic risk and emorrhagic risk scores,cognitive function, number of falls, blood pressure, nutritional assessment, athonomy, comorbidities, data on anticoagulant therapy, treatment discontinuation and clinical evaluation.
* At M3, M6, M9 and M12: • Number of falls, all treatment schedule, record of major bleeding events, record of any other bleeding events, record of other serious events, record of other non-major events, treatment discontinuation, and social and medical environment.
* Only M6 and M12: Renal function (both Cockcroft-Gault, chronic Kidney Disease, epidemiology Collaboration "CKD EPI" and the four variable modification of Diet in renal Disease equation "MDRD")

Eligibility Criteria:
Inclusion Criteria:

* Male or female patients aged 80 years and older.
* Patients with non-valvular atrial fibrillation (documented on electrocardiography or other medical evidence like medical chart, hospital discharge note, physician's letter within 3 years before enrollment).
* Followed in geriatric settings (office consultation, acute care, rehabilitation settings and nursing homes).
* Newly treated (less than 6 months) with Apixaban (5mg twice daily (or 2.5 mg twice daily for patients with 2 of the following criteria : age \> 80 years, creatinine \> 133 μmol/l, weight \< 60 kg)

Exclusion Criteria:

* Patient refusing to participate.
* Participation to a clinical trial.
* Contraindication to use of Apixaban as described in the Summary of Product Characteristics .